U.S. Markets closed

Sequenom price target raised to $5 from $4 at Wedbush

Wedbush raised its price target on Sequenom after Quest agreed to begin using the company's MaterniT21 Plus test for fetal chromosomal abnormalities. The firm notes that the deal displaces one of Sequenom's competitors, and says that it will allow Sequenom to regain clear U.S. leadership of the category while improving its path to profitability. The firm keeps an Outperform rating on Sequnom.